Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

MaSTherCell S.A.. (11/30/18). "Press Release: MaSTherCell Expands Production by Doubling Its Capacity". Gosselies.

Region Region Gosselies
  Country Belgium
Organisations Organisation MaSTherCell S.A. (Manufacturing Synergies for Therapeutic Cells)
  Group Catalent (Group)
  Organisation 2 Great Point Partners LLC
Products Product contract manufacturing (biologicals)
  Product 2 cell therapy
Persons Person Bedoret, Denis (Imcyse 202009– CEO before MaSTherCell + Quality Assistance SA + McKinsey & Co)
  Person 2 Lecocq, Jonathan (Orgenesis 201810 Communication + Marketing Manager at MaSTherCell)

MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) launched a new production wing of 600 m² at its Belgium site in the presence of the Minister-President of Wallonia, Willy Borsus. Masthercell is also backed by Great Point Partners, LLC (“GPP”), a leading healthcare investment firm based in Greenwich, Connecticut.

The expansion of the current Belgium plant will provide MaSTherCell five additional state-of-the art late stage and commercial ready clean rooms. This new wing has been designed with an Agility–by-design approach. This allows clients adaptable clinical vs commercial segregation and clean room surface optimization for both isolation of certain parts of the facility and doubling of clean room size on demand.

“We are very pleased to announce the opening of our five new clean rooms exactly on schedule with the timeline we communicated to our partners. We are very proud of this facility expansion and we have also commenced planning for a commercial manufacturing facility. I sincerely want to thank the teams for their commitment and hard work in achieving these objectives.” Said Eric Mathieu, Chief of Operations.

Each clean room of the new production wing is 30m² with independent HVAC system to ensure full autonomy and independent maintenance management. The new wing also brings additional capabilities including two development laboratories, one quality control laboratory and additional warehouse capabilities.

“Providing MaSTherCell’s quality of service in late stage and commercial manufacturing was one of our priority during the construction of the new infrastructure”, commented Dr. Denis Bedoret, Managing Director of MaSTherCell SA, “the cell therapy industry and specifically our partners are eager to have access to reliable and additional state-of-the-art facilities for their commercial projection. Our objective is to help them access the market faster with tailor made capabilities. Today, we are pleased to offer these key assets to our partners and more widely to any cell therapy company facing a lack of production or development capacities.”

About MaSTherCell

MaSTherCell S.A. is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. MaSTherCell is a subsidiary of MaSTherCell Global Inc.– a gathering of MaSTherCell in Belgium, Atvio Biotech Ltd., an Israel-based CDMO, and Curecell Co. Ltd., a Korea-based CDMO partner. Masthercell Global is majority-owned by Orgenesis Inc. (Nasdaq:ORGS), a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 diabetes. At the heart of MaSTherCell is a team of highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. The company operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. For more information, please visit

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or

MaSTherCell Contact:
Jonathan Lecocq
Communication & Marketing Manager
+32 (0) 476 81 12 44

Record changed: 2023-06-05


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Catalent (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top